83-5978-17　Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Nucleoprotein 1mg　048640

特徴

• Severe fever and thrombocytopenia syndrome virus (SFTSV) is a segmented, negative-strand RNA Phlebovirus belonging to the Bunyaviridae family.
• SFTSV is a tick-borne bunyavirus, which was first recognized in China in 2009 (Yu, XJ).
• Since 2009, reported cases of SFTSV infection have increased dramatically, occurring predominantly in China, South Korea and Japan, but also in the US and Mediterranean countries.
• Tick-borne phleboviruses (TBPVs) can classified into four distinct groups; Uukuniemi group, Bhanja group, Kaisodi group and SFTS/Heartland virus group (Matsuno et al., 2015)
• The SFTSV genome contains tri-segmented negative-sense single-stranded RNAs (-ssRNAs), including large (L), medium (M), and small (S) segments (Yu et al., 2011).
• The L segment encodes the RNA-dependent RNA polymerase (RdRp), the M segment encodes a precursor of glycoproteins (Gn and Gc), and the S segment encodes both a nucleocapsid protein (NP) and a nonstructural protein (Jiao et al., 2011).
• The Gn and Gc glycoproteins form a heterodimer and shape the spikes on the surface of the virion, for receptor binding and virus entry.
• The C-type lectin, DC-SIGN, has been identified as one of the factors for SFTSV attachment and entry into cells (Hofmann et al., 2013).
• The nucleocapsid protein (NP) is essential for viral replication; it facilitates viral RNA encapsidation and is responsible for the formation of the ribonucleoprotein complex (Zhou et al., 2013).
• The N protein is highly immunogenic and conserved among all isolates in each of the phleboviruses.
• Therefore, N protein is often selected as a target of antigen and antibody detection (Fukuma et al., 2016).
• Currently, there is no treatment for SFTSV infection and it is recognized by the World Health Organization as an emerging highly pathogenic virus, which presents a significant threat to human health (WHO).
• The viral RNA level in sera of patients with SFTS is strongly associated with clinical outcomes and diagnostic tools with high sensitivity and specificity are needed in disease endemic areas.
• Applications:Suitable for use in ELISA and Lateral Flow.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.